A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05428969
• Other study ID #: FP2CLI004
• Secondary ID: 2021-002104-12
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: June 2, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2023
• Source: Faron Pharmaceuticals Ltd
• Contact: Inka Pawlitzky, PhD
• Phone: +358 2 4695151
• Email: inka.pawlitzky[@]faron.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

Description:

This is a multicenter Phase 1/2 open-label, study to assess the safety, tolerability and preliminary efficacy of increasing doses of bexmarilimab (FP-1305) in patients with intermediate, high or very high-risk MDS, CMML with 10-19 % marrow blasts, CMML/MDS with failure to hypomethylating agent (HMA), or in patients with newly diagnosed AML non-fit for induction therapy or relapsed/refractory AML. The Phase 1 part of the study will identify a safe and tolerable bexmarilimab dose amongst four predefined dose levels using a bayesian optimal interval (BOIN) dose escalation design to identify the maximum tolerated dose (MTD) of bexmarilimab when administered in combination with SoC. The Phase 2 of the study is an expansion phase to further evaluate the safety and preliminary efficacy of bexmarilimab treatment at RP2D combined with SoC and will follow a Simon's 2-stage design for each of the indications selected to continue forward from Phase 1. This design allows for the investigation of bexmarilimab activity and preliminary response assessments tailored to each indication and allows early stopping in case of futility using a minimum number of patients. Patients from Phase 1, with the selected indication to be investigated in Phase 2, that have been treated at RP2D may be counted towards the number of patients for Phase 2. Both study phases consist of a screening period, a treatment period, an end of treatment (EoT) as safety follow-up and disease progression/survival follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 181
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient = 18 years of age who presents with one of the following conditions:
• Morphologically confirmed diagnosis of MDS with revised International Prognostic Scoring System (rIPSS) risk categories: intermediate, high and very high.
• Morphologically confirmed diagnosis of CMML-2 with indication for azacitidine treatment.
• CMML and MDS patient with response failure to HMA or therapy regimen including HMA.
• Morphologically confirmed diagnosis of r/r AML following at least 1 line of prior therapies with indication for azacitidine treatment.
• Morphologically confirmed diagnosis of AML in patients unfit for induction therapy with indication for azacitidine-venetoclax treatment.
• Leukocyte count < 20 x10^9/L (< 25 x10^9/L for newly diagnosed AML). Hydroxycarbamide use is permitted to meet this criterion in MDS and AML but not in CMML.
• Adequate renal function.
• Adequate liver function.

Exclusion Criteria:

• Patient with acute promyelocytic leukemia (APL) or myeloproliferative CMML as defined by leukocyte count > 13 x10^9/L.
• Eastern Cooperative Oncology Group (ECOG) performance status >2 (except newly diagnosed AML where ECOG 3 is allowed for patients < 75 years).
• Allogeneic transplantation less than 6 months prior screening.
• Patient with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
• The patient requires systemic corticosteroid (=10 mg/day prednisone or equivalent) or other immunosuppressive treatment.
• Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than 14 days or five half-lives (whichever is shorter) from a small molecule targeted therapy or oral anticancer chemotherapy before the first study treatment.
• Any immunotherapy or investigational therapy within preceding 28 days from the first study treatment.
• Pregnant or lactating women.
• History of chronic ulcers or clinically relevant liver disease leading to Child Pugh Score C or higher.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes
• Preleukemia
• Relapsed/Refractory AML

Intervention

Drug:
• Bexmarilimab
Intravenous
• Azacitidine
As per label, subcutaneous
• Venetoclax
Oral

Locations

Country	Name	City	State
Finland	Helsinki University Hospital	Helsinki
Finland	Kuopio University Hospital	Kuopio
Finland	Oulu University Hospital	Oulu
Finland	Tampere University Hospital	Tampere
United States	Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina
United States	City of Hope National Medical Center	Duarte	California
United States	University of Texas, MD Anderson Cancer Center	Houston	Texas
United States	Yale Cancer Center	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Faron Pharmaceuticals Ltd

Countries where clinical trial is conducted

United States,  Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reporting of incidence and frequency of dose limiting toxicities (DLTs).		From study start to end of Cycle 1 (each cycle is 28 days)
Primary	Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE).		From study start to 30 days after end of treatment (EOT)
Primary	Complete response (CR) rate for MDS and CMML-2.		From study start to 30 days after EOT
Primary	Overall response rate (ORR) for MDS and CMML failure to prior HMA.		From study start to 30 days after EOT
Primary	Complete remission with incomplete blood recovery (CRi) for r/r AML.		From study start to 30 days after EOT
Primary	Minimal residual disease (MRD) status for newly diagnosed AML.		From study start to 30 days after EOT
Secondary	Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and SAEs.		From study start to 30 days after EOT
Secondary	Clinical efficacy measures based on progression free survival analyses defined as the time from study start to the date of documented disease progression or death from any cause, whichever occurs first, up to 2 years.		24 months from study start
Secondary	Clinical efficacy measures based on overall survival analyses defined as the length measured from study start to death from any cause up to 2 years.		24 months from study start
Secondary	Anti-bexmarilimab antibody positivity occurrence rate pre-dose and at defined timepoints during treatment.		24 months from study start
Secondary	Serum concentrations of bexmarilimab at defined timepoints pre-dose and post-dose of single and repeat bexmarilimab administrations using peripheral blood.		From study start to end of Cycle 2 (each cycle is 28 days)